Ok, I found a pretty good link about
Apparently, a 24 month trial with 60mg/6 mo injections showed about
a 5.6% increase of Bone Mass Density vs. -1% for a placebo.
I dunno.... for all of the side effects, risk of osteonecrosis of the jaw (to the extent of requiring a dentist's sign off before treatment), that seems (to this engineer) a pretty small benefit.
How much change in bone mass density (BMD) represents an issue, I wonder? Is 7% enough to make the difference between fracturing or not? Man, that seems unlikely.
So, let's I'm at 58% of target BMD now (my worst reading). With Prolia, it could go up to about
64%. Without it, might drop to 57%. How much change of fracture risk might that represent?
The T score is used to show how many standard deviations an area is from a max BMD for a 30 year old. T score of -1 to -2.5 is oste
openia, less than -2.5 is osteoporosis.
My T score dropped from baseline -1 average to -1.7,-2.3, and -3.1 in some areas now, so that's pretty significant and diagnosed as oste
openia. Playing with Excel a bit, increasing the BMD% from 58 to 64 (absolute 6 point increase) takes the T score from -3.1 to -2.6, still at concern level. Decreasing by 1% to 57% takes it from -3.1 to -3.2, a negligible change for the worse.
So far, I guess I'm not really seeing the benefit of it in the simple numbers. This should be an interesting conversation with the med onc.
IGRT by IMRT, 44 done 8/28/13: 50.4 Gy pelvic nodes, 79.2 Gy prostate
ADT2 3 yrs: Lupron/Casodex 5/1/13
Age 56: 55@Dx 4/16/13-
Bx 6/12 pos G9=5+4 (80%, 60%), 4+5 (2 at 100%, 80%, 10%), PNI+
3T MRI: Bilateral EPE, NVB+, SV-, LN-, cT3a
Date PSA fPSA
2/6/14 <0.01, T<10
8/13 <0.1 (ADT2, post-RT)
3/13 5.2 12% PCA3=31
9/12 4.1 15%